Fondaparinux sodium combined with conventional therapy improves subchorionic hematoma with protein S deficiency.

IF 1.4 4区医学 Q4 ENGINEERING, BIOMEDICAL

Technology and Health Care Pub Date : 2024-07-30 DOI:10.3233/THC-241035

Yan Tan, Zhenjiao Yan, Minhong Chen, Yinglan Wang

{"title":"Fondaparinux sodium combined with conventional therapy improves subchorionic hematoma with protein S deficiency.","authors":"Yan Tan, Zhenjiao Yan, Minhong Chen, Yinglan Wang","doi":"10.3233/THC-241035","DOIUrl":null,"url":null,"abstract":"Background: Fondaparinux sodium can prevent and treat acute illnesses and venous thromboembolism in patients undergoing surgery. At present, no studies have reported on treating subchorionic hematoma combined with protein S deficiency using fondaparinux sodium.Objective: To investigate the clinical efficacy of fondaparinux sodium in the treatment of patients with subchorionic hematoma combined with protein S deficiency.Methods: This single-center, open-ended, and prospective study enrolled 78 patients with subchorionic hematoma and protein S deficiency. They were randomly assigned to the treatment and control groups. The control group received conventional treatment, and the observation group received subepithelial injections of fondaparinux sodium (2.5 mg/day) based on conventional treatment. After 30 days of continuous treatment, the hematoma was evaluated by ultrasonography.Results: After treatment with fondaparinux sodium, a significant improvement in subchorionic hematoma was observed in the observation group compared with that in the control group (p< 0.05). A substantial improvement in prothrombin time and activated partial thromboplastin time was observed in the observation group after fondaparinux sodium treatment (p< 0.05). Furthermore, after fondaparinux sodium treatment, the duration of hematoma maintenance and incidence of adverse pregnancy outcomes were significantly reduced in the observation group compared with that in the control group (p< 0.05).Conclusion: With a favorable safety profile, fondaparinux sodium is effective in treating subchorionic hematoma combined with protein S deficiency. The results provide new ideas and methods for treating this disease, which is worthy of further promotion and application in clinical practice.","PeriodicalId":48978,"journal":{"name":"Technology and Health Care","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Technology and Health Care","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3233/THC-241035","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Fondaparinux sodium can prevent and treat acute illnesses and venous thromboembolism in patients undergoing surgery. At present, no studies have reported on treating subchorionic hematoma combined with protein S deficiency using fondaparinux sodium.

Objective: To investigate the clinical efficacy of fondaparinux sodium in the treatment of patients with subchorionic hematoma combined with protein S deficiency.

Methods: This single-center, open-ended, and prospective study enrolled 78 patients with subchorionic hematoma and protein S deficiency. They were randomly assigned to the treatment and control groups. The control group received conventional treatment, and the observation group received subepithelial injections of fondaparinux sodium (2.5 mg/day) based on conventional treatment. After 30 days of continuous treatment, the hematoma was evaluated by ultrasonography.

Results: After treatment with fondaparinux sodium, a significant improvement in subchorionic hematoma was observed in the observation group compared with that in the control group (p< 0.05). A substantial improvement in prothrombin time and activated partial thromboplastin time was observed in the observation group after fondaparinux sodium treatment (p< 0.05). Furthermore, after fondaparinux sodium treatment, the duration of hematoma maintenance and incidence of adverse pregnancy outcomes were significantly reduced in the observation group compared with that in the control group (p< 0.05).

Conclusion: With a favorable safety profile, fondaparinux sodium is effective in treating subchorionic hematoma combined with protein S deficiency. The results provide new ideas and methods for treating this disease, which is worthy of further promotion and application in clinical practice.

查看原文本刊更多论文

磺达肝癸钠联合常规疗法可改善蛋白 S 缺乏的绒毛膜下血肿。

背景：磺达肝癸钠可以预防和治疗手术患者的急性疾病和静脉血栓栓塞。目前，还没有关于使用磺达肝癸钠治疗绒毛膜下血肿合并蛋白 S 缺乏症的研究报道：探讨磺达肝癸钠治疗绒毛膜下血肿合并蛋白 S 缺乏症患者的临床疗效：这项单中心、开放性、前瞻性研究共纳入了 78 例绒毛膜下血肿合并蛋白 S 缺乏症患者。他们被随机分配到治疗组和对照组。对照组接受常规治疗，观察组在常规治疗的基础上接受磺达肝癸钠皮下注射（2.5 毫克/天）。连续治疗 30 天后，通过超声波检查评估血肿情况：结果：经磺达肝癸钠治疗后，观察组绒毛膜下血肿较对照组明显改善（P< 0.05）。在使用磺达肝癸钠治疗后，观察组的凝血酶原时间和活化部分凝血活酶时间均有明显改善（p< 0.05）。此外，与对照组相比，观察组在接受磺达肝癸钠治疗后，血肿维持时间和不良妊娠结局的发生率明显减少（P< 0.05）：结论：磺达肝癸钠治疗绒毛膜下血肿合并蛋白S缺乏症具有良好的安全性。结论：磺达肝癸钠治疗绒毛膜下血肿合并蛋白 S 缺乏症具有良好的安全性，为治疗该病提供了新的思路和方法，值得在临床上进一步推广和应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Technology and Health Care HEALTH CARE SCIENCES & SERVICES-ENGINEERING, BIOMEDICAL

CiteScore

2.10

自引率

6.20%

发文量

282

审稿时长

>12 weeks

期刊介绍： Technology and Health Care is intended to serve as a forum for the presentation of original articles and technical notes, observing rigorous scientific standards. Furthermore, upon invitation, reviews, tutorials, discussion papers and minisymposia are featured. The main focus of THC is related to the overlapping areas of engineering and medicine. The following types of contributions are considered: 1.Original articles: New concepts, procedures and devices associated with the use of technology in medical research and clinical practice are presented to a readership with a widespread background in engineering and/or medicine. In particular, the clinical benefit deriving from the application of engineering methods and devices in clinical medicine should be demonstrated. Typically, full length original contributions have a length of 4000 words, thereby taking duly into account figures and tables. 2.Technical Notes and Short Communications: Technical Notes relate to novel technical developments with relevance for clinical medicine. In Short Communications, clinical applications are shortly described. 3.Both Technical Notes and Short Communications typically have a length of 1500 words. Reviews and Tutorials (upon invitation only): Tutorial and educational articles for persons with a primarily medical background on principles of engineering with particular significance for biomedical applications and vice versa are presented. The Editorial Board is responsible for the selection of topics. 4.Minisymposia (upon invitation only): Under the leadership of a Special Editor, controversial or important issues relating to health care are highlighted and discussed by various authors. 5.Letters to the Editors: Discussions or short statements (not indexed).